Antibodies recognizing tau
AssigneeProthena Biosciences Limited
InventorsTarlochan S. Nijjar, Robin BARBOUR, Philip James DOLAN, III, Yue LIU, Svetlana ALEXANDER, Mark E. RENZ
Life of this patent
Estimating the term…
Abstract
The invention provides antibodies that specifically bind tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.
Claims45
An isolated antibody specifically binding to human tau, comprising:
- a mature heavy chain variable region comprising CDR-H1 comprising SEQ ID NO:8, CDR-H2 comprising SEQ ID NO:9 or SEQ ID NO:149, and CDR-H3 comprising SEQ ID NO:10, wherein the heavy chain variable region is at least 90% identical to SEQ ID NO:18;
- and
- a mature light chain variable region comprising CDR-L1 comprising SEQ ID NO:12, CDR-L2 comprising SEQ ID NO:
- 150, 151, 153, 156, 158, 159, 160, 163, 165, 166, 167, 168, 169, 170, 171, 172, 173 or 174, and CDR-L3 comprising SEQ ID NO:14, wherein the light chain variable region is at least 90% identical to SEQ ID NO:122.
5-8. (canceled)
10-12. (canceled)
(canceled)
20-21. (canceled)
29-30. (canceled)
34-36. (canceled)
40-42. (canceled)
(canceled)
48-50. (canceled)
52-56. (canceled)
58-61. (canceled)
A method of producing an antibody that specifically binds to human tau at an epitope within a motif of the formula KXXSXXNX(K/H)H (SEQ ID NO:191) or KIGSLDNITH (SEQ ID NO:194) comprising immunizing an animal with human tau or a fragment thereof to produce antibodies and screening for an antibody of the produced antibodies that specifically binds within the motif.
65-73. (canceled)
Dependencies are inferred from the claim text.